The two new rules of "simple contract renewal" and "non-exclusive drug bidding" have been implemented for the first time
Due to the epidemic, the 2022 NHI negotiations have been postponed to January 5-8, 2023, and the negotiations will be held from January 5 to 8, 2023, at the end of the month. The first time I've ever seen this, I've never seen it before. During the negotiation period, every morning around 8:00, outside the negotiation venue will be gathered waiting to enter the pharmaceutical companies negotiators, they carry bags, holding a draft paper, calculator bag, get together to sign in line. Reporters learned from the scene, four days of national health insurance negotiations, each day's focus is different. The first day of negotiations focus on antiviral, respiratory, anesthesia drugs; January 6 focus on cardiovascular, orthopedic and immune disease drugs; January 7 focus on rare diseases and oncology, is one of the focus of the negotiations; the last day of the negotiations to the pCms. Typically, the negotiation time for each pharmaceutical company is about 20-30 minutes. After the end of the negotiations, many representatives of pharmaceutical companies involved in the negotiations, said "feel good", "not much pressure", "the rate of reduction in the expected", and representatives of pharmaceutical companies said "The company's main goal is to provide the best possible service to its customers. In addition to the representatives of pharmaceutical companies, the negotiation venue also gathered a lot of people in the pharmaceutical industry. A pharmaceutical industry analyst told reporters at the scene: "This year I am particularly concerned about the 'simple renewal' of the situation." "Simple renewal" is one of the new highlights of this year's health insurance negotiations. 2022 June 29, the National Health Insurance Bureau issued "negotiated drug renewal rules", clear exclusive varieties of simple renewal rules. According to the provisions of the agreement will expire on December 31, 2022, and at the same time to meet the exclusive drugs, the agreement period of the fund's actual expenditures did not exceed the budget of the fund expenditures (the enterprise estimated value, the same below) 200%, the next two years of the fund expenditures of the budget of a reasonable increase in five conditions of the drug, you can carry out a simple renewal of the contract, the renewal of the contract is valid for two years. Some industry analysts have analyzed that "simple renewal" helps to simplify the negotiation process, improve the efficiency of renewal, and ease the pressure of administrative approval and corporate reporting. Some of the new indications of innovative drugs are expected not to renegotiate, but through the "simple renewal" rules directly into the medical insurance. This is an important benefit for drug companies. A representative of a pharmaceutical company participating in the "non-exclusive drug bidding" told reporters that their negotiations were not smooth: "We have been 'bidding', depending on how low the price can be.These are the first time I've ever seen a drug in the market.
"Non-exclusive drugs bidding" is another new regulation of the health insurance negotiations. "Non-exclusive drug bidding rules" pointed out that the drugs through bidding into the drug catalog, take the lowest of the enterprise offer as the generic drug payment standard. If an enterprise's offer is lower than 70% of the willingness to pay, the 70% of the willingness to pay will be used as the payment standard for the drug. This means that if one of the drug companies participating in the "non-exclusive drug bidding" offer a lower price, other drug companies will also be passive to this low price into the medical insurance.Anti-cancer drugs, rare disease drugs become the focus of negotiations
According to the National Health Insurance Bureau previously announced the list of 2022 national health insurance negotiation **** 343 kinds of drugs formally through the formal review, including 198 kinds of directory of Western drugs and pCms and 145 kinds of directory of Western drugs and pCms. Pfizer's new crown oral drug Paxlovid, millions of dollars a shot of CAR-T drugs, PD-1/PD-L1 class of antitumor drugs, high-value rare disease drugs and other attention. On the night of January 8, the National Health Insurance Bureau issued a news release, Paxlovid ultimately due to the manufacturer Pfizer Investments Ltd. offer high, the negotiations were not successful. Previously, Paxlovid has been approved by the State Drug Administration on February 1, 2022 with conditions, Beijing, Shanghai and other places will Paxlovid into the temporary medical insurance. According to the "Circular on Optimizing Medical Insurance Policies Related to Treatment Costs for Patients with Novel Coronavirus Infections after the Implementation of "Class B B Control"" issued jointly by the State Medical Insurance Bureau (SMIB) and relevant departments, all therapeutic drugs in the "Diagnostic and Treatment Plan for Novel Coronavirus Infections (Trial Implementation of the 10th Edition)" include Paxlovid, Azulfidine Tablets, Monoravir Capsules, and Paxlovid. All the therapeutic drugs in the New Coronavirus Infection Diagnostic and Treatment Program (Trial 10th Edition), including Paxlovid, Azulfidine Tablets, Monoravir Capsules, and Dispersing Cold and Resolving Dampness Pellets, will be paid for by Medicare until March 31, 2023 on a temporary basis. The negotiations ushered in the main event on the second and third days, during which companies involved in the negotiations, including Bayer Pharmaceuticals, Baiyang Pharmaceuticals, Xi'an Janssen, Yangzijiang Pharmaceuticals, Hai Rong Pharmaceuticals, Jichuan Pharmaceuticals, Bazhiji Divine State, Simcere Pharmaceuticals, Junshi Bio, etc. The State Medical Insurance Bureau has previously announced that it has passed the "National Medical Insurance Bureau" (NHIB). The State Medical Insurance Bureau previously announced the preliminary form of review of the list of drugs, these companies involved in the negotiation of drugs involving a variety of anti-cancer drugs, as well as some of the rare diseases of high-value drugs. There are also 19 drugs for rare diseases in the NHI negotiations, including drugs for spinal muscular atrophy (SMA), Castleman disease, Fabry disease, Gosheimer's disease, multiple sclerosis and other rare diseases. For example, Roche Pharmaceuticals' SMA drug Risperdal Oral Solution in bulk participated in last year's national health insurance negotiations, but ultimately failed to succeed. Shandong Province drug and equipment procurement platform shows that Roche has previously reduced the price of risperdal oral solution with loose from 10,000/branch to 10,000/branch. Since 2018, the National Health Insurance Bureau through negotiations will be 19 kinds of rare disease drugs into the health insurance drug directory, the average rate of reduction of up to a year in the health insurance negotiations, Bojian company research and development production of SMA therapeutic drugs Nosinasone sodium injection from 700,000 / needle down to 10,000 / needle, when the National Health Insurance Bureau negotiator Zhang Jinni's speech, "every small group should not be abandoned! "Touched a lot of people.